Qube Research & Technologies LTD Bluebird Bio, Inc. Transaction History

Qube Research & Technologies LTD

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$1.32 - $4.83 $1.48 Million - $5.43 Million	1,124,574 New	1,124,574 $1.55 Million
Q1 2023 May 15, 2023	BUY	$3.14 - $8.22 $576,312 - $1.51 Million	183,539 Added 33.44%	732,319 $2.33 Million
Q4 2022 Feb 14, 2023	BUY	$5.77 - $8.49 $3.17 Million - $4.66 Million	548,780 New	548,780 $3.8 Million
Q2 2022 Aug 15, 2022	BUY	$2.94 - $5.23 $808,544 - $1.44 Million	275,015 Added 211.06%	405,319 $1.68 Million
Q1 2022 May 09, 2022	BUY	$4.07 - $10.6 $530,337 - $1.38 Million	130,304 New	130,304 $632,000
Q1 2021 May 14, 2021	SELL	$16.59 - $33.89 $1.12 Million - $2.29 Million	-67,455 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$27.5 - $37.92 $1.29 Million - $1.78 Million	46,998 Added 229.74%	67,455 $2.92 Million
Q3 2020 Nov 12, 2020	BUY	$34.44 - $43.75 $18,700 - $23,756	543 Added 2.73%	20,457 $1.1 Million
Q2 2020 Aug 14, 2020	BUY	$27.12 - $45.97 $22,157 - $37,557	817 Added 4.28%	19,914 $1.22 Million
Q1 2020 May 15, 2020	BUY	$26.16 - $63.5 $437,630 - $1.06 Million	16,729 Added 706.46%	19,097 $878,000
Q4 2019 Feb 13, 2020	BUY	$46.96 - $61.67 $111,201 - $146,034	2,368 New	2,368 $208,000

146

63.3M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $644M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.